RBCC Initiates Search for Medical Business Consultant
NOKOMIS, Fla.--(BUSINESS WIRE)-- As Rainbow Coral Corp. (OTCBB: RBCC) works to expand its biotechnology initiatives internationally, the company is seeking a medical business director to help the company penetrate the international personalized medicine industry.
“Initially, our focus will be on North American markets,” said RBCC CEO Patrick Brown. “We have big plans for expansion, and we need someone with strong ties to the medical community both here and abroad to help us execute.”
The company’s research indicates an underdeveloped market in North America for personalized medicine products, services and innovations, making the sector ripe for innovation and growth. RBCC is looking for an experienced medical business consultant to assist with crafting a workable market strategy that fits the company’s goals.
In the U.S., RBCC is already hard at work delivering new breakthroughs in personalized medicine. The company recently signed a joint venture agreement with TheraKine Ltd., the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. RBCC’s joint venture partner, Nano3D BioSciences, announced a distribution agreement with St. Louis-based scientific products distributor MIDSCI to sell its revolutionary BioAssembler product line in the multi-billion-dollar U.S biotechnology market.
For more information on RBCC’s biotechnology projects, please visit www.rainbowbiosciences.com/investors.html.
Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Bristol Myers Squibb Co. (NYSE: BMY ) , Biogen Idec Inc. (Nasdaq: BIIB ) , Abbott Laboratories (NYSE: ABT ) and Amgen Inc. (Nasdaq: AMGN ) .
About Rainbow BioSciences
Rainbow BioSciences, LLC, is a wholly owned subsidiary of Rainbow Coral Corp. (OTCBB: RBCC). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.
Rainbow Coral Corp.
Patrick Brown, 850-269-7230
President and CEO
KEYWORDS: United States North America Florida